Published in Mov Disord on September 01, 2006
Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch Arztebl Int (2012) 3.16
The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov (2013) 2.00
Expectancy and the Treatment of Depression: A Review of Experimental Methodology and Effects on Patient Outcome. Curr Psychiatry Rev (2010) 1.38
Placebo and the new physiology of the doctor-patient relationship. Physiol Rev (2013) 1.20
The history and future of deep brain stimulation. Neurotherapeutics (2008) 1.11
Deep brain stimulation of the human reward system for major depression--rationale, outcomes and outlook. Neuropsychopharmacology (2014) 1.06
Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J Physiol (2009) 1.05
Measurement of patient-centered outcomes in Parkinson's disease: what do patients really want from their treatment? Parkinsonism Relat Disord (2010) 1.01
Teaching neurons to respond to placebos. J Physiol (2016) 0.89
Expectation modulates the effect of deep brain stimulation on motor and cognitive function in tremor-dominant Parkinson's disease. PLoS One (2013) 0.79
Diffusion Tensor Imaging-Based Thalamic Segmentation in Deep Brain Stimulation for Chronic Pain Conditions. Stereotact Funct Neurosurg (2016) 0.79
Occipital nerve stimulation for chronic migraine--a systematic review and meta-analysis. PLoS One (2015) 0.79
Deep brain stimulation for movement disorders: update on recent discoveries and outlook on future developments. J Neurol (2015) 0.79
A randomized double-blind crossover trial of deep brain stimulation of the subcallosal cingulate gyrus in patients with treatment-resistant depression: a pilot study of relapse prevention. J Psychiatry Neurosci (2015) 0.78
Effect of expectancy and personality on cortical excitability in Parkinson's disease. Mov Disord (2013) 0.76
Placebo Response is Driven by UCS Revaluation: Evidence, Neurophysiological Consequences and a Quantitative Model. Sci Rep (2016) 0.76
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Does this dyspneic patient in the emergency department have congestive heart failure? JAMA (2005) 6.14
The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet (2009) 6.02
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg (2011) 3.30
Effect of school-based physical activity interventions on body mass index in children: a meta-analysis. CMAJ (2009) 3.19
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
Staffing levels in not-for-profit and for-profit long-term care facilities: does type of ownership matter? CMAJ (2005) 2.33
Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol (2002) 1.83
Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. Am J Ophthalmol (2003) 1.79
[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain (2003) 1.70
Cost-effectiveness of continuous positive airway pressure therapy for moderate to severe obstructive sleep apnea/hypopnea. Arch Intern Med (2006) 1.68
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 1.65
Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol (2003) 1.64
Auto-titrating versus standard continuous positive airway pressure for the treatment of obstructive sleep apnea: results of a meta-analysis. Sleep (2004) 1.62
Nurse staffing levels and hospital mortality in critical care settings: literature review and meta-analysis. J Adv Nurs (2006) 1.60
The importance of autonomic symptoms in trigeminal neuralgia. Clinical article. J Neurosurg (2011) 1.60
SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics (2013) 1.58
Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry (2010) 1.57
The effect of a bolus dose of etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med (2010) 1.56
DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54
The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol (2003) 1.52
Determinants of hospital length of stay among patients with pneumonia admitted to a large Canadian hospital from 1991 to 2001. Can Respir J (2005) 1.52
Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology (2013) 1.50
A controlled trial of arthroscopic surgery for osteoarthritis of the knee. Arthroscopy (2002) 1.45
Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br J Psychiatry (2010) 1.45
Dietary measures and exercise training contribute to improvement of endothelial function and atherosclerosis even in patients given intensive pharmacologic therapy. J Cardiopulm Rehabil (2006) 1.44
Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol (2005) 1.42
Clustering of Parkinson disease: shared cause or coincidence? Arch Neurol (2004) 1.42
The value of thoracic computed tomography scans in clinical diagnosis: a prospective study. Can Respir J (2006) 1.39
Percutaneous radiofrequency trigeminal rhizotomy in a patient with an implanted cardiac pacemaker. Anesth Analg (2004) 1.39
A metaanalysis comparing the results of pallidotomy performed using microelectrode recording or macroelectrode stimulation. J Neurosurg (2002) 1.39
Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res (2002) 1.36
Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription. J Virol (2004) 1.30
Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord (2008) 1.29
Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair. Mov Disord (2003) 1.28
Deep brain stimulation for movement disorders. Front Integr Neurosci (2012) 1.24
The placebo effect in Parkinson's disease. Trends Neurosci (2002) 1.24
Regulation of aquaporin-4 in a traumatic brain injury model in rats. J Neurosurg (2003) 1.23
Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain (2011) 1.20
Brown-Sèquard syndrome produced by C3-C4 cervical disc herniation: a case report and review of the literature. Spine (Phila Pa 1976) (2008) 1.19
Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol (2011) 1.19
The placebo effect in neurological disorders. Lancet Neurol (2002) 1.18
Vegetative state and minimally conscious state: a review of the therapeutic interventions. Stereotact Funct Neurosurg (2010) 1.18
Percutaneous trigeminal nerve radiofrequency rhizotomy guided by computerized tomography fluoroscopy. Technical note. J Neurosurg (2003) 1.17
Nuclear factor 90 mediates activation of the cellular antiviral expression cascade. AIDS Res Hum Retroviruses (2002) 1.16
Protein phosphatase-1 dephosphorylates the C-terminal domain of RNA polymerase-II. J Biol Chem (2002) 1.14
The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA. Proc Natl Acad Sci U S A (2003) 1.13
Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care (2006) 1.13
Chromatin remodeling and modification during HIV-1 Tat-activated transcription. Curr HIV Res (2003) 1.12
Nuclear protein phosphatase-1 regulates HIV-1 transcription. J Biol Chem (2003) 1.12
Medial forebrain bundle stimulation as a pathophysiological mechanism for hypomania in subthalamic nucleus deep brain stimulation for Parkinson's disease. Neurosurgery (2009) 1.12
Reducing hardware-related complications of deep brain stimulation. Can J Neurol Sci (2005) 1.10
Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol (2008) 1.10
Does this patient with liver disease have cirrhosis? JAMA (2012) 1.09
Functional imaging in Parkinson disease. Neurology (2008) 1.08
MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology (2010) 1.07
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov Disord (2004) 1.06
Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry (2004) 1.06
HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem J (2002) 1.05
VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse (2003) 1.02
Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism Relat Disord (2013) 1.02
Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord (2010) 1.01
Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord (2008) 1.00
Synthesis of novel amino and acetyl amino-4-methylcoumarins and evaluation of their antioxidant activity. Eur J Med Chem (2005) 0.99
Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol (2004) 0.98
Electrocardiogram artifacts caused by deep brain stimulation. Can J Neurol Sci (2004) 0.97
Neuroepithelial cysts presenting with movement disorders: two cases. Can J Neurol Sci (2003) 0.97
Young onset Parkinson's disease. Practical management of medical issues. Parkinsonism Relat Disord (2007) 0.96
Rising incidence of hospital-reported drug-facilitated sexual assault in a large urban community in Canada. Retrospective population-based study. Can J Public Health (2004) 0.95
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res (2012) 0.95
Up-regulation of TLR2 and TLR4 in dendritic cells in response to HIV type 1 and coinfection with opportunistic pathogens. AIDS Res Hum Retroviruses (2011) 0.95
Medical student selection: choice of a semi-structured panel interview or an unstructured one-on-one interview. Med Teach (2005) 0.94
The biochemical bases for reward. Implications for the placebo effect. Eval Health Prof (2002) 0.94
Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord (2008) 0.94
Socioeconomic status and hospital utilization among younger adult pneumonia admissions at a Canadian hospital. BMC Health Serv Res (2006) 0.93
Ca(2+) activation and tension cost in myofilaments from mouse hearts ectopically expressing enteric gamma-actin. Am J Physiol Heart Circ Physiol (2002) 0.93
Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol (2007) 0.93
Microlesion effect as a predictor of the effectiveness of subthalamic deep brain stimulation for Parkinson's disease. Stereotact Funct Neurosurg (2012) 0.93
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging (2011) 0.92
Hepatitis B and/or C co-infection in HIV infected patients: a study in a tertiary care centre from South India. Indian J Med Res (2013) 0.92
Primary hepatocyte culture supports hepatitis C virus replication: a model for infection-associated hepatocarcinogenesis. Hepatology (2010) 0.92